Long

MMED impending NASDAQ uplisting

Mis à jour
Psychedelics have the potential to revolutionize mental health as we know it. Recent research has shown that Psilocybin, DMT, LSD, Ketamine and MDM shown to be effective to treat conditions such as depression, anxiety, PTSD and more. MMED is currently conducting preliminary research to develop psychedelic therapies such as LSD microdosing and a new research project which combines doses of LSD and MDMA.

As legal and regulatory dominos begin to topple, MMED is poised to make some big moves. Currently with the highest market cap in the space at $3.98 billion, MMED is still listed on the smaller NEO exchange, but it is in the application process to get uplisted to the NASDAQ. This further exposure could be huge for the company.

MMED just broke out of its lower consolidation range, and if this bullishness continues, we could see it testing levels of resistance in the coming weeks. With a big boost for MMED and the whole space, this could be the breakout we have been waiting for. Let's see how it performs when it hits upward resistance levels and keep an eye on the volume.

The macros are super bullish on this one so I am going to continue to hold regardless of whether it pulls back or not.

As always this is NOT TRADING ADVICE

Disclosure: As an early investor at 0.42, MMED has been my most successful trade to date.
After taking profits in the $5-6.50 range at the last peak, I have been increasing my position during its consolidation between $3.5-4.5.
Note
MMED getting close to testing upward resistance around $6. A breakout above 6.50 would be very bullish.
Note
MMED has been making some good progress closing over $5 the last two days. Some more volume would be nice!
GrowthSupport and ResistanceTrend Analysis

Clause de non-responsabilité